Fellowship · New York, NY
Sponsored by New York Presbyterian Hospital
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.
Blood · 2022 · 1,363 citations · Barbara Pro
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
The New England journal of medicine · 2021 · 1,440 citations · Markus Y Mapara
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.
The New England journal of medicine · 2023 · 550 citations · Ran Reshef
Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study.
The Lancet. Oncology · 2022 · 800 citations · David Fogelman
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021 · 841 citations · Dawn L Hershman
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
Annals of oncology : official journal of the European Society for Medical Oncology · 2024 · 393 citations ·
Exagamglogene Autotemcel for Severe Sickle Cell Disease.
The New England journal of medicine · 2024 · 351 citations · Markus Y Mapara
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
The New England journal of medicine · 2023 · 435 citations · Nicole Lamanna